

Supporting Information for

**Highly efficient construction of spirocyclic chromanone-pyrrolidines
via Cu(I)/TF-BiphamPhos-catalyzed asymmetric 1,3-dipolar
cycloaddition**

Tang-Lin Liu, Zhao-Lin He, and Chun-Jiang Wang*

E-mail: cjwang@whu.edu.cn

Table of Contents

I.	General Remarks	2
II.	General Procedure for Asymmetric 1,3-Dipolar Cycloaddition of Azomethine Ylides with (<i>E</i>)-3-Alkylidene chroman-4-ones	2-17
III.	X-ray Crystal Structures of (2' <i>R</i> ,3 <i>R</i> ,4' <i>R</i> ,5' <i>R</i>)- 3aa	17
IV.	References	18
V.	¹ H NMR and ¹³ C NMR Spectra	19-60
VI.	HPLC Chromatograms	61-102

General Remarks.


^1H NMR spectra were recorded on a VARIAN Mercury 300 MHz spectrometer in chloroform-*d*. Chemical shifts are reported in ppm with the internal TMS signal at 0.0 ppm as a standard. The data are reported as (s = single, d = double, t = triple, q = quartet, m = multiple or unresolved, brs = broad single, coupling constant(s) in Hz, integration). ^{13}C NMR spectra were recorded on a VARIAN Mercury 75 MHz spectrometer in chloroform-*d*. Chemical shifts are reported in ppm with the internal chloroform signal at 77.0 ppm as a standard. Commercially obtained reagents were used without further purification. All reactions were monitored by TLC with silica gel-coated plates. Diastereomeric ratios were determined from crude ^1H NMR or HPLC analysis. Enantiomeric excesses were determined by HPLC, using a chiralcel AD-H column, a chirapak AS-H column with hexane and *i*-PrOH as solvents. Ligands **L1** and **L2** were prepared according to the literature procedure reported by us.^[1] (*E*)-3-Alkylidene chroman-4-ones were prepared according to the literature procedure.^[2] The racemic adducts were attained by using AgOAc/(±)-TF-BiphamPhos as the catalyst. The absolute (2'*R*,3*R*,4'*R*,5'*R*)-**3aa** achieved by AgOAc/(*S*)-TF-BiphamPhos was determined unequivocally according to the X-ray diffraction analysis, and those of other adducts were deduced on the basis of these results.

General Procedure for racemic 1,3-Dipolar Cycloaddition of Azomethine Ylides with (*E*)-3-Alkylidene chroman-4-ones Catalyzed by AgOAc/(±)-TF-BiphamPhos Complex.

Under argon atmosphere, (±)-TF-BiphamPhos (4.6 mg, 0.0072 mmol) and AgOAc (1.0 mg, 0.006 mmol) were dissolved in 2 mL DCM, and stirred at room temperature for about 1h. Then, imine substrate (0.4 mmol), Et₃N (0.03 mmol) and (*E*)-3-alkylidene chroman-4-ones (0.2 mmol) were added sequentially. Once starting material was consumed (monitored by TLC), the organic solvent was removed and the residue was purified by column chromatography to give the cycloadduct, which was used as the racemic sample for the chiral HPLC analysis.

General Procedure for Asymmetric 1,3-Dipolar Cycloaddition of Azomethine Ylides with (*E*)-3-Alkylidene chroman-4-ones Catalyzed by AgOAc/(*S*)-TF-BiphamPhos Complex.

Under argon atmosphere (*S*)-TF-BiphamPhos **L5** (5.8 mg, 0.0072 mmol) and Cu(CH₃CN)₄BF₄ (2.0 mg, 0.006 mmol) were dissolved in 2 mL DCM, and stirred at room temperature for about 1h. Then, imine substrate (0.4 mmol), Et₃N (0.03 mmol) and (*E*)-3-alkylidene chroman-4-ones (0.2 mmol) were added sequentially. Once starting material was consumed (monitored by TLC), the mixture was filtered through celite and the filtrate was concentrated to dryness. The product purified by column chromatography to give the corresponding cycloaddition product, which was then directly analyzed by chiral HPLC to determine the enantiomeric excess.




(3aa)

(2'*R*,3*R*,4'*R*,5'*R*)-methyl 2'-(4-chlorophenyl)-4-oxo-4'-phenylspiro[chroman-3,3'-pyrrolidine]-5'-carboxylate

The title compound was prepared according to the general procedure as described above in 85% yield. m.p. 60-62 °C; [α]_D²⁵ = +91.3 (*c* 1.08, CHCl₃); ¹H NMR (CDCl₃, TMS, 300 MHz) δ 7.46 (d, *J* = 8.1 Hz, 1H), 7.32-7.26 (m, 6H), 7.10 (d, *J* = 8.7 Hz, 2H), 6.97 (d, *J* = 8.1 Hz, 2H), 6.78 (t, *J* = 7.5 Hz, 1H), 6.66 (d, *J* = 8.7 Hz, 1H), 4.84 (s, 1H), 4.53 (d, *J* = 8.1 Hz, 1H), 4.38 (d, *J* = 8.4 Hz, 1H), 4.16 (d, *J* = 12.0 Hz, 1H), 3.84 (d, *J* = 11.7 Hz, 1H), 3.78 (s, 3H); ¹³C NMR (CDCl₃, TMS, 75 MHz) δ 192.59, 173.49, 160.42, 136.97, 136.35, 135.84, 133.67, 129.34, 128.95, 128.74, 127.99, 127.86, 127.38, 121.43, 121.26, 117.17, 73.26, 69.79, 59.66, 53.63, 52.71, 51.93; IR (KBr) ν 3677, 3622, 3019, 2977, 2400, 1734, 1606, 1520, 1477, 1415, 1216, 1046, 928, 757, 669 cm⁻¹. The product was analyzed by HPLC to determine the enantiomeric excess: 91% ee (Chiralcel AS-H, *i*-propanol/hexane = 10/90, flow rate


1.0 mL/min, $\lambda = 220$ nm); $t_r = 21.75$ and 38.18 min.



(3ba)

(2'*R*,3*R*,4'*R*,5'*R*)-methyl 2'-(2-chlorophenyl)-4-oxo-4'-phenylspiro[chroman-3,3'-pyrrolidine]-5'-carboxylate

The title compound was prepared according to the general procedure as described above in 81% yield. m.p. 99-100 °C; $[\alpha]_D^{25} = +33.8$ (c 1.24, CHCl_3); ^1H NMR (CDCl_3 , TMS, 300 MHz) δ 7.53 (d, $J = 7.5$ Hz, 1H), 7.37-7.19 (m, 7H), 7.07-6.93 (m, 3H), 6.75 (d, $J = 7.5$ Hz, 1H), 6.63 (d, $J = 8.4$ Hz, 1H), 5.51 (s, 1H), 4.52 (d, $J = 7.5$ Hz, 1H), 4.42 (d, $J = 7.5$ Hz, 1H), 4.18 (d, $J = 12.0$ Hz, 1H), 3.87 (d, $J = 12.0$ Hz, 1H), 3.80 (s, 3H); ^{13}C NMR (CDCl_3 , TMS, 75 MHz) δ 192.83, 173.21, 160.67, 136.55, 135.49, 133.83, 129.05, 128.62, 127.65, 126.81, 126.37, 120.89, 117.06, 72.41, 64.87, 64.50, 59.50, 52.50; IR (KBr) ν 3678, 3621, 3020, 2978, 2400, 1733, 1606, 1521, 1478, 1416, 1217, 1046, 928, 757, 669 cm^{-1} . The product was analyzed by HPLC to determine the enantiomeric excess: 89% ee (Chiralcel AD-H, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, $\lambda = 220$ nm); $t_r = 11.94$ and 23.73 min.




(3ca)

(2'*R*,3*R*,4'*R*,5'*R*)-methyl 2'-(3-chlorophenyl)-4-oxo-4'-phenylspiro[chroman-3,3'-pyrrolidine]-5'-carboxylate

The title compound was prepared according to the general procedure as described above in 87% yield. m.p. 56-58 °C; $[\alpha]_D^{25} = +92.3$ (c 0.73, CHCl_3); ^1H NMR (CDCl_3 , TMS, 300 MHz) δ 7.48 (dd, $J = 1.5$ Hz, 8.1 Hz, 1H), 7.32-7.23 (m, 7H), 7.12-7.07 (m,


2H), 6.96-6.94 (m, 2H), 6.77 (d, $J = 7.5$ Hz, 1H), 6.68 (d, $J = 8.4$ Hz, 1H), 4.81 (s, 1H), 4.54 (d, $J = 8.1$ Hz, 1H), 4.38 (d, $J = 8.4$ Hz, 1H), 4.16 (d, $J = 11.7$ Hz, 1H), 3.83 (d, $J = 11.7$ Hz, 1H), 3.79 (s, 3H); ^{13}C NMR (CDCl_3 , TMS, 75 MHz) δ 192.25, 173.11, 160.15, 140.12, 136.12, 135.65, 133.49, 128.93, 128.73, 128.50, 128.30, 127.81, 127.65, 127.11, 125.71, 121.17, 116.92, 72.96, 69.79, 64.13, 59.37, 52.51, 51.53; IR (KBr) ν 3680, 3619, 3018, 2978, 2399, 1734, 1606, 1521, 1478, 1416, 1216, 1047, 928, 757, 669 cm^{-1} . The product was analyzed by HPLC to determine the enantiomeric excess: 89% ee (Chiralcel AD-H, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, $\lambda = 220$ nm); $t_r = 11.23$ and 23.05 min.



(3da)

(2'*R*,3*R*,4'*R*,5'*R*)-methyl 4-oxo-2',4'-diphenylspiro[chroman-3,3'-pyrrolidine]-5'-carboxylate


The title compound was prepared according to the general procedure as described above in 85% yield. m.p. 128-130 °C; $[\alpha]_D^{25} = +119.0$ (c 1.15, CHCl_3); ^1H NMR (CDCl_3 , TMS, 300 MHz) δ 7.44 (d, $J = 7.5$ Hz, 1H), 7.34-7.14 (m, 8H), 7.00-6.99 (m, 3H), 6.74-6.62 (m, 2H), 4.85 (s, 1H), 4.54 (d, $J = 8.1$ Hz, 1H), 4.37 (d, $J = 8.1$ Hz, 1H), 4.18 (d, $J = 12.0$ Hz, 1H), 3.83 (d, $J = 11.4$ Hz, 1H), 3.78 (s, 3H), 2.90 (brs, 1H); ^{13}C NMR (CDCl_3 , TMS, 75 MHz) δ 192.74, 173.34, 160.30, 137.89, 136.43, 135.37, 138.71, 128.56, 127.79, 127.71, 127.59, 127.13, 121.17, 120.96, 16.94, 76.32, 73.21, 70.76, 64.34, 59.60, 52.50, 52.26; IR (KBr) ν 3682, 3625, 3020, 2980, 2400, 1735, 1610, 1518, 1476, 1420, 1223, 1046, 928, 757, 669 cm^{-1} . The product was analyzed by HPLC to determine the enantiomeric excess: 90% ee (Chiralcel AD-H, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, $\lambda = 220$ nm); $t_r = 16.76$ and 49.71 min.



(3ea)

(2'*R*,3*R*,4'*R*,5'*R*)-methyl 2'-(4-methoxyphenyl)-4-oxo-4'-phenylspiro[chroman-3,3'-pyrrolidine]-5'-carboxylate

The title compound was prepared according to the general procedure as described above in 90% yield. m.p. 59-61 °C; $[\alpha]_D^{25} = +132.9$ (*c* 1.04, CHCl₃); ¹H NMR (CDCl₃, TMS, 300 MHz) δ 7.49 (d, *J* = 7.8 Hz, 1H), 7.36-7.23 (m, 8H), 7.09 (d, *J* = 8.1 Hz, 1H), 6.77 (d, *J* = 7.5 Hz, 1H), 6.68 (d, *J* = 8.1 Hz, 1H), 6.56 (d, *J* = 8.1 Hz, 1H), 4.85 (s, 1H), 4.55 (d, *J* = 8.7 Hz, 1H), 4.38 (d, *J* = 8.4 Hz, 1H), 4.20 (d, *J* = 11.4 Hz, 1H), 3.89 (d, *J* = 12.9 Hz, 1H), 3.80 (s, 3H), 3.67 (s, 3H), 2.85 (brs, 1H); ¹³C NMR (CDCl₃, TMS, 75 MHz) δ 192.44, 172.95, 159.83, 158.55, 135.99, 134.91, 129.51, 128.46, 128.24, 128.12, 126.71, 120.76, 120.54, 116.49, 112.64, 72.74, 69.68, 63.71, 58.97, 54.69, 52.04, 51.73; IR (KBr) ν 3682, 3621, 3020, 2976, 2400, 1736, 1688, 1606, 1523, 1478, 1425, 1216, 1047, 929, 758, 669 cm⁻¹. The product was analyzed by HPLC to determine the enantiomeric excess: 94% ee (Chiralcel AD-H, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, λ = 220 nm); *t*_r = 26.92 and 60.81 min.




(3fa)

(2'*R*,3*R*,4'*R*,5'*R*)-methyl 4-oxo-4'-phenyl-2'-*p*-tolylspiro[chroman-3,3'-pyrrolidine]-5'-carboxylate

The title compound was prepared according to the general procedure as described above in 86% yield. m.p. 137-140 °C; $[\alpha]_D^{25} = +129.9$ (*c* 1.44, CHCl₃); ¹H NMR (CDCl₃, TMS, 300 MHz) δ 7.44 (d, *J* = 8.1 Hz, 1H), 7.32-7.20 (m, 6H), 7.01 (d, *J* =


7.8 Hz, 2H), 6.81 (d, $J = 7.8$ Hz, 2H), 6.73 (d, $J = 7.5$ Hz, 1H), 6.65 (d, $J = 8.1$ Hz, 1H), 4.83 (s, 1H), 4.52 (d, $J = 8.7$ Hz, 1H), 4.37 (d, $J = 8.4$ Hz, 1H), 4.19 (d, $J = 12.0$ Hz, 1H), 3.83 (d, $J = 12.0$ Hz, 1H), 3.77 (s, 3H), 2.13 (s, 3H); ^{13}C NMR (CDCl_3 , TMS, 75 MHz) δ 192.18, 173.32, 160.23, 137.36, 136.33, 135.20, 134.80, 128.59, 128.50, 128.30, 127.52, 127.09, 121.14, 120.83, 116.87, 73.01, 70.28, 64.13, 53.37, 52.40, 52.16, 20.82; IR (KBr) ν 3683, 3620, 3020, 2979, 2399, 1735, 1607, 1523, 1479, 1416, 1219, 1047, 929, 758, 669 cm^{-1} . The product was analyzed by HPLC to determine the enantiomeric excess: 89% ee (Chiralcel AD-H, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, $\lambda = 220$ nm); $t_r = 11.37$ and 44.17 min.



(3ga)

(2'*R*,3*R*,4'*R*,5'*R*)-methyl 4-oxo-4'-phenyl-2'-*o*-tolylspiro[chroman-3,3'-pyrrolidine]-5'-carboxylate


The title compound was prepared according to the general procedure as described above in 95% yield. m.p. 131-134 °C; $[\alpha]_D^{25} = +64.2$ (c 1.28, CHCl_3); ^1H NMR (CDCl_3 , TMS, 300 MHz) δ 7.46 (d, $J = 7.8$ Hz, 1H), 7.36-7.26 (m, 4H), 7.20-7.15 (m, 2H), 6.94 (d, $J = 7.2$ Hz, 1H), 6.87 (t, $J = 7.2$ Hz, 1H), 6.79 (t, $J = 7.5$ Hz, 1H), 6.71 (t, $J = 7.5$ Hz, 1H), 6.60 (d, $J = 8.4$ Hz, 1H), 5.16 (s, 1H), 4.59 (d, $J = 8.4$ Hz, 1H), 4.37 (d, $J = 8.4$ Hz, 1H), 4.13 (d, $J = 12.0$ Hz, 1H), 3.81 (d, $J = 12.0$ Hz, 1H), 3.78 (s, 3H), 2.81 (brs, 1H), 2.26 (s, 3H); ^{13}C NMR (CDCl_3 , TMS, 75 MHz) δ 173.05, 160.19, 136.49, 136.30, 135.23, 130.08, 128.74, 128.52, 127.62, 127.41, 127.22, 127.09, 125.78, 121.00, 116.63, 73.30, 65.72, 64.32, 59.89, 53.07, 52.52, 19.33; IR (KBr) ν 3680, 3619, 3019, 2977, 2400, 1735, 1609, 1524, 1478, 1415, 1216, 1046, 928, 757, 669 cm^{-1} . The product was analyzed by HPLC to determine the enantiomeric excess: 89% ee (Chiralcel AD-H, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, $\lambda = 220$ nm); $t_r = 10.51$ and 12.82 min.



(3ha)

(2'R,3R,4'R,5'R)-methyl 4-oxo-4'-phenyl-2'-*m*-tolylspiro[chroman-3,3'-pyrrolidine]-5'-carboxylate

The title compound was prepared according to the general procedure as described above in 94% yield. m.p. 141-144 °C; $[\alpha]_D^{25} = +103.7$ (*c* 1.46, CHCl₃); ¹H NMR (CDCl₃, TMS, 300 MHz) δ 7.43 (dd, *J* = 1.8 Hz, 8.1 Hz, 1H), 7.33-7.19 (m, 6H), 6.99-6.88 (m, 3H), 6.78 (d, *J* = 7.5 Hz, 1H), 6.72 (t, *J* = 7.5 Hz, 1H), 6.64 (d, *J* = 8.7 Hz, 1H), 4.81 (s, 1H), 4.53 (d, *J* = 8.7 Hz, 1H), 4.37 (d, *J* = 8.1 Hz, 1H), 4.17 (d, *J* = 12.0 Hz, 1H), 3.81 (d, *J* = 12.0 Hz, 1H), 3.77 (s, 3H), 2.89 (brs, 1H), 2.08 (s, 3H); ¹³C NMR (CDCl₃, TMS, 75 MHz) δ 192.56, 173.16, 160.24, 137.60, 137.14, 136.36, 135.18, 128.61, 128.54, 128.39, 127.60, 127.50, 127.04, 124.69, 121.25, 120.80, 116.75, 73.07, 70.66, 64.19, 59.57, 52.38, 52.11, 21.00; IR (KBr) ν 3679, 3619, 3021, 2978, 2401, 1735, 1606, 1520, 1477, 1415, 1217, 1046, 928, 758, 669 cm⁻¹. The product was analyzed by HPLC to determine the enantiomeric excess: 89% ee (Chiralcel AD-H, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, λ = 220 nm); *t*_r = 9.83 and 21.72 min.




(3ia)

(2'R,3R,4'R,5'R)-methyl 2'-(naphthalen-1-yl)-4-oxo-4'-phenylspiro[chroman-3,3'-pyrrolidine]-5'-carboxylate

The title compound was prepared according to the general procedure as described above in 93% yield. m.p. 178-181 °C; $[\alpha]_D^{25} = -68.4$ (*c* 1.82, CHCl₃); ¹H NMR

(CDCl₃, TMS, 300 MHz) δ 8.03 (d, J = 8.7 Hz, 1H), 7.56-7.43 (m, 3H), 7.36-7.15 (m, 8H), 7.07 (d, J = 8.1 Hz, 1H), 6.81 (d, J = 7.5 Hz, 1H), 6.37 (t, J = 7.5 Hz, 1H), 6.19 (d, J = 8.1 Hz, 1H), 5.76 (s, 1H), 4.65 (d, J = 9.3 Hz, 1H), 4.41 (d, J = 8.7 Hz, 1H), 4.29 (d, J = 11.7 Hz, 1H), 3.73 (d, J = 12.0 Hz, 1H), 3.66 (s, 3H), 2.84 (brs, 1H); ¹³C NMR (CDCl₃, TMS, 75 MHz) δ 192.11, 173.16, 160.02, 135.87, 134.67, 134.56, 133.14, 130.94, 128.59, 128.17, 127.52, 126.55, 125.80, 125.26, 124.95, 124.81, 122.75, 120.84, 120.61, 116.41, 73.82, 63.61, 63.46, 60.21, 52.38, 51.76; IR (KBr) ν 3683, 3621, 3019, 2980, 2400, 1736, 1686, 1606, 1517, 1478, 1425, 1215, 1040, 928, 758, 669 cm⁻¹. The product was analyzed by HPLC to determine the enantiomeric excess: 90% ee (Chiralcel AD-H, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, λ = 220 nm); t_r = 20.91 and 40.67 min.




(3ja)

(2'*R*,3*R*,4'*R*,5'*R*)-methyl 2'-(naphthalen-2-yl)-4-oxo-4'-phenylspiro[chroman-3,3'-pyrrolidine]-5'-carboxylate

The title compound was prepared according to the general procedure as described above in 83% yield. m.p. 107-110 °C; $[\alpha]_D^{25} = +73.4$ (c 1.21, CHCl₃); ¹H NMR (CDCl₃, TMS, 300 MHz) δ 7.64-7.61 (m, 3H), 7.53 (d, J = 15.4 Hz, 1H), 7.39-7.29 (m, 9H), 7.10 (t, J = 8.1 Hz, 1H), 6.63 (d, J = 8.1 Hz, 1H), 6.57 (d, J = 7.5 Hz, 1H), 5.06 (s, 1H), 4.68 (d, J = 8.7 Hz, 1H), 4.66 (d, J = 8.7 Hz, 1H), 4.29 (d, J = 12.0 Hz, 1H), 3.90 (d, J = 12.0 Hz, 1H), 3.84 (s, 3H), 2.95 (brs, 1H); ¹³C NMR (CDCl₃, TMS, 75 MHz) δ 188.80, 168.84, 155.69, 131.81, 128.34, 128.10, 124.25, 124.13, 123.34, 123.13, 122.93, 122.75, 122.54, 121.28, 120.95, 116.66, 116.42, 112.31, 68.57, 66.01, 59.74, 55.27, 48.07, 47.51; IR (KBr) ν 3681, 3620, 3020, 2979, 2400, 1737, 1680, 1616, 1514, 1478, 1425, 1216, 1046, 928, 759, 669 cm⁻¹. The product was analyzed by HPLC to determine the enantiomeric excess: 86% ee (Chiralcel AD-H,


i-propanol/hexane = 30/70, flow rate 1.0 mL/min, λ = 220 nm); t_r = 21.06 and 57.83 min.



(3ka)

(2'*R*,3*R*,4'*R*,5'*R*)-methyl 2'-(furan-2-yl)-4-oxo-4'-phenylspiro[chroman-3,3'-pyrrolidine]-5'-carboxylate

The title compound was prepared according to the general procedure as described above in 86% yield. m.p. 69-72 °C; $[\alpha]_D^{25} = +129.0$ (*c* 1.15, CHCl₃); ¹H NMR (CDCl₃, TMS, 300 MHz) δ 7.67 (dd, *J* = 1.5 Hz, 7.8 Hz, 1H), 7.35-7.27 (m, 6H), 7.04 (d, *J* = 1.6 Hz, 1H), 6.86 (d, *J* = 6.6 Hz, 1H), 6.76 (d, *J* = 8.4 Hz, 1H), 6.11 (d, *J* = 3.0 Hz, 1H), 6.02-6.01 (m, 1H), 4.89 (s, 1H), 4.52 (d, *J* = 7.5 Hz, 1H), 4.32 (d, *J* = 8.1 Hz, 1H), 4.20 (d, *J* = 12.0 Hz, 1H), 3.85 (d, *J* = 12.0 Hz, 1H), 3.76 (s, 3H), 3.06 (brs, 1H); ¹³C NMR (CDCl₃, TMS, 75 MHz) δ 192.00, 173.15, 160.57, 150.72, 141.90, 136.41, 135.51, 128.71, 128.58, 127.62, 127.30, 121.13, 120.59, 117.14, 110.04, 108.59, 72.33, 64.39, 63.42, 58.83, 52.55, 51.78; IR (KBr) ν 3680, 3621, 3019, 2981, 2400, 1737, 1687, 1609, 1513, 1478, 1425, 1214, 1040, 928, 758, 669 cm⁻¹. The product was analyzed by HPLC to determine the enantiomeric excess: 90% ee (Chiralcel AD-H, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, λ = 220 nm); t_r = 13.61 and 57.64 min.




(3ab)

(2'*R*,3*R*,4'*R*,5'*R*)-methyl 2'-(4-chlorophenyl)-4'-(4-methoxyphenyl)-4-oxospiro-

[chroman-3,3'-pyrrolidine]-5'-carboxylate

The title compound was prepared according to the general procedure as described above in 88% yield. $[\alpha]_D^{25} = +58.4$ (*c* 1.40, CHCl₃); ¹H NMR (CDCl₃, TMS, 300 MHz) δ 7.45 (d, *J* = 7.5 Hz, 1H), 7.30-7.22 (m, 3H), 7.09 (d, *J* = 8.7 Hz, 2H), 6.97 (d, *J* = 8.1 Hz, 2H), 6.86 (d, *J* = 8.1 Hz, 2H), 6.78 (t, *J* = 7.2 Hz, 1H), 6.67 (d, *J* = 8.7 Hz, 1H), 4.82 (s, 1H), 4.49 (d, *J* = 7.2 Hz, 1H), 4.32 (d, *J* = 6.6 Hz, 1H), 4.19 (d, *J* = 12.0 Hz, 1H), 3.85 (d, *J* = 13.2 Hz, 1H), 3.78 (s, 3H); ¹³C NMR (CDCl₃, TMS, 75 MHz) δ 192.41, 173.29, 160.19, 158.89, 136.82, 135.60, 133.40, 130.86, 129.52, 129.06, 127.77, 127.12, 121.17, 121.04, 116.96, 114.01, 72.94, 69.37, 64.11, 59.46, 55.15, 52.50, 50.99; IR (KBr) ν 3680, 3621, 3019, 2979, 2400, 1735, 1685, 1606, 1517, 1478, 1426, 1215, 1044, 929, 758, 668 cm⁻¹. The product was analyzed by HPLC to determine the enantiomeric excess: 92% ee (Chiralcel AD-H, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, λ = 220 nm); *t*_r = 22.85 and 39.31 min.




(3ac)

(2'*R*,3*R*,4'*R*,5'*R*)-methyl 2',4'-bis(4-chlorophenyl)-4-oxospiro[chroman-3,3'-pyrrolidine]-5'-carboxylate

The title compound was prepared according to the general procedure as described above in 95% yield. m.p. 60-62 °C; $[\alpha]_D^{25} = +103.2$ (*c* 1.10, CHCl₃); ¹H NMR (CDCl₃, TMS, 300 MHz) δ 7.46 (d, *J* = 7.8 Hz, 1H), 7.28-7.22 (m, 5H), 7.09 (d, *J* = 8.1 Hz, 2H), 6.98 (d, *J* = 8.1 Hz, 2H), 6.86 (d, *J* = 8.1 Hz, 2H), 6.78 (m, 1H), 6.68 (d, *J* = 8.1 Hz, 1H), 4.82 (s, 1H), 4.49 (d, *J* = 8.4 Hz, 1H), 4.35 (m, 1H), 4.19 (d, *J* = 12.0 Hz, 1H), 3.85 (d, *J* = 11.7 Hz, 1H), 3.78 (s, 3H); ¹³C NMR (CDCl₃, TMS, 75 MHz) δ 191.93, 172.92, 160.20, 136.89, 135.76, 134.45, 133.57, 129.89, 129.12, 128.88, 127.85, 127.24, 121.35, 121.04, 117.00, 72.80, 69.12, 63.63, 52.10, 50.68, 29.84; IR (KBr) ν 3683, 3621, 302, 2980, 2400, 1736, 1606, 1517, 1478, 1425, 1215, 1040, 928,


758, 669 cm^{-1} . The product was analyzed by HPLC to determine the enantiomeric excess: 94% ee (Chiralcel AS-H, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 220 nm); t_r = 41.15 and 48.18 min.



(3ad)

(2'R,3R,4'R,5'R)-methyl 4'-(2-chlorophenyl)-2'-(4-chlorophenyl)-4-oxospiro-[chroman-3,3'-pyrrolidine]-5'-carboxylate


The title compound was prepared according to the general procedure as described above in 87% yield. m.p. 146-148 °C; $[\alpha]_D^{25} = +85.7$ (*c* 1.68, CHCl_3); ^1H NMR (CDCl_3 , TMS, 300 MHz) δ 7.62 (t, J = 11.1 Hz, 2H), 7.47 (t, J = 7.2 Hz, 2H), 7.29 (d, J = 7.2 Hz, 1H), 7.27-7.17 (m, 3H), 6.93 (t, J = 8.4 Hz, 1H), 6.78 (t, J = 7.5 Hz, 1H), 6.45 (d, J = 8.1 Hz, 1H), 4.93 (d, J = 4.5 Hz, 1H), 4.75 (d, J = 6.9 Hz, 1H), 4.23 (s, 1H), 4.12 (d, J = 11.7 Hz, 1H), 3.93 (s, 3H), 3.86 (d, J = 11.7 Hz, 1H), 3.08 (brs, 1H); ^{13}C NMR (CDCl_3 , TMS, 75 MHz) δ 193.69, 173.79, 160.35, 136.68, 135.74, 135.35, 134.81, 133.79, 130.24, 129.49, 129.10, 127.89, 127.25, 121.35, 120.84, 117.12, 73.00, 66.90, 58.39, 52.97, 49.70; IR (KBr) ν 3679, 3620, 3018, 2983, 2403, 1736, 1683, 1606, 1513 1473, 1425, 1215, 1040, 929, 758, 668 cm^{-1} . The product was analyzed by HPLC to determine the enantiomeric excess: 92% ee (Chiralcel AS-H, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 220 nm); t_r = 11.47 and 43.77 min.



(3ae)

(2'R,3R,4'R,5'R)-methyl 4'-(3-chlorophenyl)-2'-(4-chlorophenyl)-4-oxospiro-[chroman-3,3'-pyrrolidine]-5'-carboxylate

The title compound was prepared according to the general procedure as described above in 88% yield. m.p. 66-68 °C; $[\alpha]_D^{25} = +110.3$ (*c* 0.76, CHCl₃); ¹H NMR (CDCl₃, TMS, 300 MHz) δ 7.38 (d, *J* = 7.5 Hz, 1H), 7.24-7.02 (m, 5H), 7.01 (d, *J* = 8.1 Hz, 2H), 6.90 (d, *J* = 8.1 Hz, 2H), 6.72 (d, *J* = 7.5 Hz, 1H), 6.61 (t, *J* = 7.8 Hz, 1H), 4.76 (s, 1H), 4.50 (d, *J* = 8.1 Hz, 1H), 4.26 (d, *J* = 8.4 Hz, 1H), 4.13 (d, *J* = 12.0 Hz, 1H), 3.77 (d, *J* = 12.0 Hz, 1H), 3.75 (s, 3H); ¹³C NMR (CDCl₃, TMS, 75 MHz) δ 192.18, 173.06, 160.37, 138.39, 136.81, 135.98, 134.84, 133.77, 130.19, 129.34, 128.83, 128.03, 127.43, 126.96, 121.55, 121.15, 117.20, 73.00, 69.60, 63.98, 59.61, 52.81, 51.23; IR (KBr) ν 3680, 3620, 3020, 2981, 2400, 1735, 1685, 1605, 1515, 1477, 1425, 1215, 1039, 929, 759, 669 cm⁻¹. The product was analyzed by HPLC to determine the enantiomeric excess: 91% ee (Chiralcel AS-H, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 220 nm); *t*_r = 20.98 and 46.34 min.




(3af)

(2'R,3R,4'R,5'R)-methyl 2'-(4-chlorophenyl)-4'-(furan-2-yl)-4-oxospiro[chroman-3,3'-pyrrolidine]-5'-carboxylate

The title compound was prepared according to the general procedure as described above in 89% yield. m.p. 146-148 °C; $[\alpha]_D^{25} = +115.3$ (*c* 0.66, CHCl₃); ¹H NMR (CDCl₃, TMS, 300 MHz) δ 7.49 (d, *J* = 7.5 Hz, 1H), 7.40 (s, 1H), 7.29 (t, *J* = 7.5 Hz, 1H), 7.06 (d, *J* = 8.1 Hz, 2H), 6.96 (d, *J* = 8.4 Hz, 2H), 6.80 (t, *J* = 7.8 Hz, 1H), 6.69 (d, *J* = 8.7 Hz, 1H), 6.32 (s, 1H), 6.25 (s, 1H), 4.84 (s, 1H), 4.57 (d, *J* = 8.4 Hz, 1H), 4.40-4.35 (m, 2H), 3.98 (d, *J* = 12.0 Hz, 1H), 3.80 (s, 3H); ¹³C NMR (CDCl₃, TMS, 75 MHz) δ 192.03, 172.81, 160.54, 150.31, 142.69, 136.64, 135.90, 133.64, 129.22, 127.93, 127.33, 121.47, 121.11, 117.25, 110.68, 109.20, 72.37, 69.55, 62.74, 60.29,


52.71, 45.51; IR (KBr) ν 3680, 3620, 3019, 2980, 2399, 1736, 1606, 1519, 1478, 1425, 1215, 1040, 928, 758, 669 cm^{-1} . The product was analyzed by HPLC to determine the enantiomeric excess: 91% ee (Chiralcel AS-H, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 220 nm); t_r = 17.72 and 33.19 min.



(3ag)

(2'R,3R,4'R,5'R)-methyl 2'-(4-chlorophenyl)-4-oxo-4'-propylspiro[chroman-3,3'-pyrrolidine]-5'-carboxylate

The title compound was prepared according to the general procedure as described above in 75% yield. $[\alpha]_D^{25} = +86.7$ (c 0.72, CHCl₃); ¹H NMR (CDCl₃, TMS, 300 MHz) δ 7.46 (d, J = 8.4 Hz, 1H), 7.37 (t, J = 7.5 Hz, 1H), 6.98 (s, 4H), 6.87-6.83 (m, 2H), 4.74 (s, 1H), 4.48 (d, J = 11.1 Hz, 2H), 3.86 (s, 3H), 3.71 (d, J = 9.0 Hz, 1H), 3.29 (q, J = 8.4 Hz, 1H), 2.24 (brs, 1H), 1.55-1.49 (m, 2H), 1.34-1.21 (m, 1H), 0.89 (t, J = 6.6 Hz, 3H); ¹³C NMR (CDCl₃, TMS, 75 MHz) δ 191.90, 173.97, 160.29, 137.93, 135.66, 133.27, 128.99, 127.75, 127.42, 121.41, 121.20, 117.17, 70.93, 67.53, 64.81, 59.15, 52.37, 45.47, 29.79, 21.28, 14.17; IR (KBr) ν 3682, 3621, 3020, 2976, 2400, 1736, 1688, 1606, 1523, 1478, 1425, 1216, 1047, 929, 758, 669 cm^{-1} . The product was analyzed by HPLC to determine the enantiomeric excess: 94% ee (Chiralcel AD-H, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, λ = 220 nm); t_r = 7.35 and 11.10 min.




(3ah)

(2'R,3R,4'R,5'R)-methyl 2'-(4-chlorophenyl)-4-oxo-4'-styrylspiro[chroman-

3,3'-pyrrolidine]-5'-carboxylate

The title compound was prepared according to the general procedure as described above in 88% yield. m.p. 133-134 °C; $[\alpha]_D^{25} = +159.3$ (*c* 1.28, CHCl₃); ¹H NMR (CDCl₃, TMS, 300 MHz) δ 7.45 (dd, *J* = 1.5 Hz, 7.8 Hz, 1H), 7.36-7.20 (m, 6H), 7.05-6.97 (m, 4H), 6.81-6.78 (m, 2H), 6.62 (d, *J* = 15.9 Hz, 1H), 6.05 (dd, *J* = 8.7 Hz, 15.3 Hz, 1H), 4.80 (s, 1H), 4.57 (d, *J* = 11.4 Hz, 1H), 4.43 (d, *J* = 12.0 Hz, 1H), 4.10 (t, *J* = 9.0 Hz, 1H), 3.99 (d, *J* = 9.3 Hz, 1H), 3.81 (s, 3H), 2.54 (brs, 1H); ¹³C NMR (CDCl₃, TMS, 75 MHz) δ 191.47, 173.04, 160.29, 137.29, 136.37, 135.70, 134.75, 133.46, 128.95, 128.53, 127.86, 127.26, 126.37, 123.23, 121.39, 121.21, 117.11, 71.71, 68.26, 64.20, 60.66, 52.41, 49.64; IR (KBr) ν 3681, 3618, 3019, 2979, 2400, 1736, 1686, 1606, 1517, 1478, 1425, 1215, 1040, 928, 758, 669 cm⁻¹. The product was analyzed by HPLC to determine the enantiomeric excess: 93% ee (Chiralcel AD-H, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, λ = 220 nm); *t*_r = 17.88 and 34.69 min.




(3ai)

(2'*R*,3*R*,4'*R*,5'*R*)-methyl 2'-(4-chlorophenyl)-6-methyl-4-oxo-4'-phenylspiro-[chroman-3,3'-pyrrolidine]-5'-carboxylate

The title compound was prepared according to the general procedure as described above in 95% yield. m.p. 206-208 °C; $[\alpha]_D^{25} = +121.4$ (*c* 1.01, CHCl₃); ¹H NMR (CDCl₃, TMS, 300 MHz) δ 7.31-7.26 (m, 6H), 7.10 (d, *J* = 8.1 Hz, 3H), 6.99 (d, *J* = 8.7 Hz, 2H), 6.57 (d, *J* = 8.1 Hz, 1H), 4.84 (s, 1H), 4.52 (d, *J* = 8.7 Hz, 1H), 4.39 (d, *J* = 8.7 Hz, 1H), 4.15 (d, *J* = 12.0 Hz, 1H), 3.80 (d, *J* = 12.0 Hz, 1H), 3.78 (s, 3H), 2.16 (s, 3H); ¹³C NMR (CDCl₃, TMS, 75 MHz) δ 192.57, 173.27, 158.35, 136.74, 136.08, 133.43, 130.71, 129.15, 128.70, 128.50, 127.80, 127.61, 126.70, 120.68, 116.77, 72.99, 69.40, 63.97, 59.59, 52.53, 51.70, 20.19; IR (KBr) ν 3681, 3621, 3021, 2977,


2400, 1735, 1521, 1476, 1424, 1215, 1047, 929, 773, 669 cm^{-1} . The product was analyzed by HPLC to determine the enantiomeric excess: 93% ee (Chiralcel AD-H, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, λ = 220 nm); t_r = 15.56 and 21.28 min.



(3aj)

(2'*R*,3*R*,4'*R*,5'*R*)-methyl 6-chloro-2'-(4-chlorophenyl)-4-oxo-4'-phenylspiro-[chroman-3,3'-pyrrolidine]-5'-carboxylate

The title compound was prepared according to the general procedure as described above in 87% yield. $[\alpha]_D^{25} = +105.6$ (*c* 1.12, CHCl_3); ^1H NMR (CDCl_3 , TMS, 300 MHz) δ 7.45 (d, J = 2.4 Hz, 1H), 7.33-7.20 (m, 7H), 7.11-7.05 (m, 4H), 6.63 (d, J = 9.0 Hz, 1H), 4.87 (s, 1H), 4.52-4.45 (m, 2H), 4.20 (d, J = 12.0 Hz, 1H), 3.82 (d, J = 14.4 Hz, 1H), 3.79 (s, 3H); ^{13}C NMR (CDCl_3 , TMS, 75 MHz) δ 191.45, 172.77, 158.74, 135.65, 134.01, 129.12, 128.86, 128.48, 128.06, 127.89, 126.86, 126.36, 118.80, 73.06, 69.50, 64.03, 59.20, 52.76, 51.76; IR (KBr) ν 3682, 3620, 3020, 2978, 2429, 2400, 1736, 1523, 1479, 1428, 1219, 1043, 929, 773, 669 cm^{-1} . The product was analyzed by HPLC to determine the enantiomeric excess: 93% ee (Chiralcel AD-H, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, λ = 220 nm); t_r = 14.90 and 17.95 min.



(3ak)

(2*R*,3*S*,4*R*,5*R*)-methyl 2-(4-chlorophenyl)-4'-oxo-4-phenylspiro[pyrrolidine-3,3'-

thiochroman]-5-carboxylate

The title compound was prepared according to the general procedure as described above in 93% yield. $[\alpha]_D^{25} = +124.3$ (c 1.06, CHCl_3); ^1H NMR (CDCl_3 , TMS, 300 MHz) δ 7.58 (d, $J = 8.1$ Hz, 1H), 7.36-7.16 (m, 9H), 7.01-6.93 (m, 3H), 5.17 (s, 1H), 4.78 (d, $J = 7.2$ Hz, 1H), 4.40 (d, $J = 12.0$ Hz, 1H), 3.71 (s, 3H), 3.04 (d, $J = 13.8$ Hz, 1H), 2.85 (d, $J = 14.7$ Hz, 1H); ^{13}C NMR (CDCl_3 , TMS, 75 MHz) δ 192.76, 173.19, 139.76, 138.06, 135.37, 133.42, 132.90, 130.62, 130.40, 129.39, 129.06, 128.45, 127.78, 127.53, 126.30, 124.67, 66.53, 62.12, 60.15, 53.48, 52.51, 34.28; IR (KBr) ν 3683, 3621, 3019, 2980, 2400, 1736, 1686, 1606, 1517, 1478, 1425, 1215, 1040, 928, 758, 669 cm^{-1} . The product was analyzed by HPLC to determine the enantiomeric excess: 95% ee (Chiralcel AD-H, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, $\lambda = 220$ nm); $t_r = 12.40$ and 22.69 min.

X-ray Crystal Structures of (2'*R*,3*R*,4'*R*,5'*R*)-3aa






Figure 2. X-ray structure of (2'*R*,3*R*,4'*R*,5'*R*)-3aa.



For (2'*R*,3*R*,4'*R*,5'*R*)-**3aa**: $\text{C}_{26}\text{H}_{22}\text{ClNO}_4$, $M_r = 447.90$, $T = 293$ K, Orthorhombic, space group $P2_12_12_1$, $a = 9.960(9)$, $b = 12.124(11)$, $c = 18.738(16)$ Å, $V = 2263(3)$ Å³, $Z = 4$, 4436 reflections measured, 2920 unique ($R_{\text{int}} = 0.0503$) which were used in all calculations. The final $wR_2 = 0.1037$ (all data), Flack $\chi = -0.10(10)$. CCDC 828929 (**3aa**).



References

- [1] C.-J. Wang, G. Liang, Z-Y. Xue, F. Gao, *J. Am. Chem. Soc.* **2008**, *130*, 17250.
- [2] (a) K. M.Dawood, T. Fuchigami, *J. Org. Chem.*, **2001**, *66*, 7691. (b) D. Basavaiah, M. Bakthadoss, S. Pandiaraju, *chem.commun.*, **1998**, 1639. (c) S. H. Kim, S. H. Kim, J. N. Kim, *Bull. Korean Chem. Soc.* **2008**, *29*, 2039.














Solvent: CDCl₃
Temperature: 300.2 K
Pulse: delay 1.000 sec
Pulse: 28.0 degrees
Acq. time: 0.500 sec
F1: 125.763 MHz
F2: 101.626 MHz
128 repetitions
OBSERVE: C13, 75.4552827 MHz
DECOUPLE: H1, 300.0821362 MHz
F1: 125.763 MHz
F2: 101.626 MHz
Coupling: on
Continuity: on
WALTZ-16 modulated
DATA PROCESSING
Line broadening 8.0 Hz
F1: 125.763 MHz
F2: 101.626 MHz
Total time 9 hr, 10 min, 41 sec








Solvent: CDCl3
Ambient temperature
Mercury-300DB "mercury300"
Relax, delay 1.000 sec
Pulse 28.0 degrees
Acquisition time 0.000 sec
With 18181.8 Hz
144 repetitions
OBSERVE C13, 75.4552516 MHz
DECOUPLE H1, 300.0821362 MHz
Pulse program zgpg30
continuously on
WALTZ-16 modulated
DATA PROCESSING
F1 time processing 8.0 Hz
F2 time processing 0.0 Hz
F3 time processing 0.0 Hz
Total time 9 hr, 10 min, 41 sec




















c13-11-9-308
Archive directory: /export/home/jm/vnmrsys/data
Sample directory:
File: CARBON
Pulse Sequence: zgpg30
Solvent: CDCl₃
Ambient temperature:
Mercury-30088 "mercury300"
Relax: delay 1.000 sec
Pulse: zgpg30
Pulse program: zgpg30
Width: 18181.8 Hz
152 repetitions
OBSERVE: c13, 75.455871 MHz
DECOUPLE: h1, 300.0821862 MHz
SOLVENT: CDCl₃
Continuous on
WALTZ-16 modulated
DATA PROCESSING
Time: 0.00000000
Time: 0.00000000
Time: 0.00000000
Total time: 1 hr, 27 min, 30 sec





































C13-111-8-616





















111-S-63A-1








131-11-288-1






CDCl₃-11-29a
Solvent: CDCl₃
Ambient temperature
Mercury-30008 "mercury300"
Relax delay 1.000 sec
Pulse 20.000 sec
Acq. time 0.501 sec
Width 17241.4 Hz
200 repetitions
0.000 sec
DECOUPLE H1, 300.0821862 MHz
Power 40 dB
continuously on
WALTZ-16 modulated
D1 2.000 sec
Line broadening 4.0 Hz
FT size 32768
Total time 2 hr, 24 min, 8 sec







CDCl₃ - 15-11-196
Solvent: CDCl₃
Ambient temperature
Mercury-300SB "mercury300"
Pulse delay 1.000 sec
Pulse 28.0 degrees
Acq. time 0.501 sec
Width 17241.4 Hz
256 repetitions 5.455291 MHz
OBSERVED C13 300.0821962 MHz
DECOUPLE H1 300.0821962 MHz
Power 40 dB
continuously on
DATA ACQUISITION
DATA PROCESSING
Line broadening 4.0 Hz
FT size 32768
Total time 2 hr, 24 min, 8 sec









cd3-cl-9-36a
Archive directory: /export/home/nj/ymr/sy/data
Sample directory:
Filter: ORIGIN
Pulse Sequence: zgpg30
Solvent: CDCl₃
Ambient temperature
Mercury-3000B "mercury300"
Relax delay 1.000 sec
Pulse program zgpg30
Acq time 0.500 sec
Width 18181.8 Hz
128 repetitions
OBSERVE C13, 75.452349 MHz
OBSERVE H1, 500.061362 MHz
Power 40 dB
continuously on
WALTZ-16 modulated
DATA PROCESSING
F2 size 32768
Total time 1 hr, 27 min, 30 sec







Archive directory: /export/home/nu/ymf/sys/data
Sample directory:
File: PROTON
Pulse Sequence: zgpg30




Archive directory: /export/home/vu/vnmr/sys/data
Sample directory:
File: CARBON
Pulse Sequence: zgpg30
Solvent: CDCl₃
Ambient temperature
Mercury-300BB vnmrj300w
Relax. delay: 1.000 sec
Acq. time: 0.500 sec
Width: 18181.8 Hz
200 repetitions
OBSERVE: C13, 5.455271 MHz
P1: 12.00 dB, 300.0621502 MHz
Power: 40 dB
Continuously on
WALTZ-16 modulated
DATA PROCESSING: 4.0 Hz
Spectrum processing
FT size: 32768
Total time: 1 hr, 27 min, 30 sec

数据文件: F:\HPLC\DATA\LTL-3-48-50\LTL-3-48-50-220 2009-11-15 19-05-12\SIG1000002.D
样品名称: LTL-3-48

=====

操作者	: DXQ	序列行	: 2
仪器	: Instrument 1	位置	: 样品瓶 12
进样日期	: 2009-11-16 12:07:29 下午	进样次数	: 1
		进样量	: 5 µl
采集方法	: D:\LC\LTL\data\LTL-3-48-50\LTL-3-48-50-220 2009-11-15 19-05-12\ASH-10-90-10ML-220NM-60MIN.M		
最后修改	: 2009-11-16 10:41:50 上午 : DXQ		
分析方法	: F:\HPLC\DATA\LTL-3-48-50\LTL-3-48-50-220 2009-11-15 19-05-12\SIG1000002.D\DA.M (ASH-10-90-10ML-220NM-60MIN.M)		
最后修改	: 2011-1-24 10:54:02 下午		

(调用后修改)



=====

面积百分比报告

=====

峰序 : 信号
乘积因子 : 1.0000
稀释因子 : 1.0000
内标使用乘积因子和稀释因子

信号 1: VWD1 A, Wavelength=220 nm

峰 #	保留时间 [min]	类型	峰宽 [min]	峰面积 mAU *s	峰高 [mAU]	峰面积 %
1	21.752	BB	1.4485	2.13104e4	226.52090	50.1892
2	38.182	BB	3.2848	2.11498e4	89.33236	49.8108
总量 :				4.24602e4	315.85326	

=====

*** 报告结束 ***

Data File D:\LC\LTL\DATE\LTL-8-44\LTL-8-44 2010-11-15 16-27-54\070-0301.D
Sample Name: LTL-8-44B

=====


Acq. Operator	: DXQ	Seq. Line	: 3
Acq. Instrument	: Instrument 1	Location	: Vial 70
Injection Date	: 11/15/2010 5:32:04 PM	Inj	: 1
		Inj Volume	: 5 µl

Acq. Method : D:\LC\LTL\DATE\LTL-8-44\LTL-8-44 2010-11-15 16-27-54\ASH-10-90-1ML-220NM-50MIN.M

Last changed : 8/30/2010 8:44:32 AM by LTL

Analysis Method : D:\LC\LTL\DATE\LTL-8-44\LTL-8-44 2010-11-15 16-27-54\070-0301.D\DA.M (ASH-10-90-1ML-220NM-50MIN.M)

Last changed : 11/19/2010 2:37:26 PM by THL
(modified after loading)



Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VMD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	22.458	MM	1.6156	8073.06641	83.28065	6.9752
2	37.534	MM	3.8536	1.07667e5	465.64847	93.0248
Totals :				1.15740e5	548.92912	

Instrument 1 11/19/2010 2:37:31 PM THL

Data File D:\LC\LTL\DATE\LTL-9-42\LTL-9-42A 2011-02-15 20-11-47\071-0201.D
Sample Name: LTL-9-42A

=====


Acq. Operator	: LTL	Seq. Line	: 2
Acq. Instrument	: Instrument 1	Location	: Vial 71
Injection Date	: 2/15/2011 8:24:04 PM	Inj	: 1
		Inj Volume	: 5 µl

Acq. Method : D:\LC\LTL\DATE\LTL-9-42\LTL-9-42A 2011-02-15 20-11-47\ADH-30-70-1ML-220NM-70MIN.M

Last changed : 2/15/2011 10:56:36 AM by LTL

Analysis Method : D:\LC\LTL\DATE\LTL-9-42\LTL-9-42A 2011-02-15 20-11-47\071-0201.D\DA.M (ADH-30-70-1ML-220NM-70MIN.M)

Last changed : 2/16/2011 10:27:14 AM by LTL
(modified after loading)



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	12.127	NM	0.5095	4.98426e4	1630.31836	49.6966
2	23.778	NM	1.0098	5.04512e4	832.65930	50.3034


Totals : 1.00294e5 2462.97766

=====
Instrument 1 2/16/2011 10:27:18 AM LTL

Page 1 of 1

Data File D:\LC\LTL\DATE\LTL-9-41\LTL-9-41B 2011-02-16 10-32-03\062-0301.D
Sample Name: LTL-9-42B

```
=====
Acq. Operator   : LTL                               Seq. Line :    3
Acq. Instrument : Instrument 1                       Location  : Vial 62
Injection Date  : 2/16/2011 11:31:21 AM              Inj       :    1
                                                    Inj Volume: 5 µl
Acq. Method     : D:\LC\LTL\DATE\LTL-9-41\LTL-9-41B 2011-02-16 10-32-03\ADH-30-70-1ML-220NM-30MIN.M
Last changed    : 1/22/2011 10:59:12 AM by THL-7-95-97
Analysis Method : D:\LC\LTL\DATE\LTL-9-41\LTL-9-41B 2011-02-16 10-32-03\062-0301.D\DA.M (
                  ADH-30-70-1ML-220NM-30MIN.M)
Last changed    : 2/16/2011 2:45:55 PM by LTL
                  (modified after loading)
=====
```



Area Percent Report

```
=====
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs
=====
```

Signal 1: VM01 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	11.935	MM	0.5926	1.17681e5	3309.99829	94.4588
2	23.727	MM	0.9442	6903.51270	121.86088	5.5412

Totals : 1.24584e5 3431.85917

Instrument 1 2/16/2011 2:45:59 PM LTL

Page 1 of 1

Data File D:\LC\RTL\DATE\RTL-11-28\RTL-11-28 2011-06-09 12-10-08\061-0201.D
Sample Name: RTL-9-41A

=====


Acq. Operator	: LTL	Seq. Line	: 2
Acq. Instrument	: Instrument 1	Location	: Vial 61
Injection Date	: 6/9/2011 12:22:48 PM	Inj	: 1
		Inj Volume	: 5 µl

Acq. Method : D:\LC\RTL\DATE\RTL-11-28\RTL-11-28 2011-06-09 12-10-08\ADH-30-70-1ML-220NM-50MIN-NOT.M

Last changed : 6/9/2011 12:11:29 PM by hzl

Analysis Method : D:\LC\RTL\DATE\RTL-11-28\RTL-11-28 2011-06-09 12-10-08\061-0201.D\DA.M (ADH-30-70-1ML-220NM-50MIN-NOT.M)

Last changed : 6/13/2011 9:51:14 PM by LTL
(modified after loading)



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: WVD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	11.974	VV	0.4413	5.22811e4	1766.84814	49.5387
2	23.240	EE	0.8209	5.32548e4	959.32581	50.4613

Totals : 1.05536e5 2726.17395

=====
*** End of Report ***

Data File D:\LC\LTL\DATE\LTL-11-28\LTL-11-28 2011-06-09 12-10-08\062-0301.D
Sample Name: LTL-11-28A

=====


Acq. Operator	: LTL	Seq. Line	: 3
Acq. Instrument	: Instrument 1	Location	: Vial 62
Injection Date	: 6/9/2011 1:14:36 PM	Inj	: 1
		Inj Volume	: 5 µl

Acq. Method : D:\LC\LTL\DATE\LTL-11-28\LTL-11-28 2011-06-09 12-10-08\ADH-30-70-1ML-220NM-50MIN-NOT.M

Last changed : 6/9/2011 12:11:29 PM by hz1

Analysis Method : D:\LC\LTL\DATE\LTL-11-28\LTL-11-28 2011-06-09 12-10-08\062-0301.D\DA.M (ADH-30-70-1ML-220NM-50MIN-NOT.M)

Last changed : 6/13/2011 9:51:37 PM by LTL
(modified after loading)



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: WWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	11.809	EB	0.4324	6.21266e4	2136.55786	95.2202
2	23.049	EB	0.7556	3118.56201	61.55494	4.7798

Totals : 6.52451e4 2198.11280

=====
*** End of Report ***
=====

Data File D:\LC\LTLD\DATE\LTIL-8-53\LTIL-8-53A 2010-12-07 10-28-20\055-0201.D
Sample Name: LTL-8-53A

=====


Acq. Operator	: THL	Seq. Line	: 2
Acq. Instrument	: Instrument 1	Location	: Vial 55
Injection Date	: 12/7/2010 10:40:48 AM	Inj	: 1
		Inj Volume	: 5 µl

Acq. Method : D:\LC\LTLD\DATE\LTIL-8-53\LTIL-8-53A 2010-12-07 10-28-20\ADH-30-70-IML-220NM-80MIN.M

Last changed : 11/27/2010 11:06:07 AM by LTL

Analysis Method : D:\LC\LTLD\DATE\LTIL-8-53\LTIL-8-53A 2010-12-07 10-28-20\055-0201.D\DA.M (ADH-30-70-IML-220NM-80MIN.M)

Last changed : 12/7/2010 7:05:30 PM by THL
(modified after loading)



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: WWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	16.062	VB	0.6031	3.56487e4	873.00519	49.9184
2	45.899	BB	1.7280	3.57653e4	307.55499	50.0816
Totals :				7.14140e4	1180.56018	


Instrument 1 12/7/2010 7:05:34 PM THL

Page 1 of 1

Data File D:\LC\LTL\DATE\LTL-9-29\LTL-9-29A 2011-01-12 10-22-43\063-0201.D
Sample Name: LTL-9-29A

```
=====
Acq. Operator   : thl                      Seq. Line :    2
Acq. Instrument : Instrument 1              Location  : Vial 63
Injection Date  : 1/12/2011 10:35:10 AM    Inj       :    1
                                           Inj Volume: 5 µl

Acq. Method     : D:\LC\LTL\DATE\LTL-9-29\LTL-9-29A 2011-01-12 10-22-43\ADH-30-70-1ML-220NM-
60MIN.M
Last changed    : 12/7/2010 3:06:41 PM by THL
Analysis Method : D:\LC\LTL\DATE\LTL-9-29\LTL-9-29A 2011-01-12 10-22-43\063-0201.D\DA.M (
ADH-30-70-1ML-220NM-60MIN.M)
Last changed    : 1/24/2011 4:53:15 PM by LTL
                (modified after loading)
=====
```



Area Percent Report

```
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs
```

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	16.762	BB	0.6723	8.82917e4	1955.83447	95.7878
2	49.707	MM	1.9543	3882.52197	33.11037	4.2122

Totals : 9.21742e4 1988.94485

Instrument 1 1/24/2011 4:53:21 PM LTL

Page 1 of 1

Data File D:\LC\RTL\DATE\RTL-8-54-56\RTL-8-54-56A 2010-12-07 15-08-23\056-0201.D
Sample Name: RTL-8-54A

=====


Acq. Operator	: THL	Seq. Line	: 2
Acq. Instrument	: Instrument 1	Location	: Vial 56
Injection Date	: 12/7/2010 3:21:00 PM	Inj	: 1
		Inj Volume	: 5 µl

Acq. Method : D:\LC\RTL\DATE\RTL-8-54-56\RTL-8-54-56A 2010-12-07 15-08-23\ADH-30-70-1ML-22ONM-80MIN.M

Last changed : 12/7/2010 4:19:09 PM by THL
(modified after loading)

Analysis Method : D:\LC\RTL\DATE\RTL-8-54-56\RTL-8-54-56A 2010-12-07 15-08-23\056-0201.D\DA.M (ADH-30-70-1ML-22ONM-80MIN.M)

Last changed : 12/7/2010 7:03:27 PM by THL
(modified after loading)



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VMD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	25.168	EB	0.9595	2.53876e4	392.71057	49.9668
2	54.540	EB	2.0516	2.54214e4	182.84471	50.0332

Totals : 5.08090e4 575.55528

=====
*** End of Report ***

Data File D:\LC\LTL\DATE\LTL-9-29\LTL-9-29B 2011-01-12 15-46-16\064-0101.D
Sample Name: LTL-9-29B

=====


Acq. Operator	: DXQ	Seq. Line	: 1
Acq. Instrument	: Instrument 1	Location	: Vial 64
Injection Date	: 1/12/2011 3:47:39 PM	Inj	: 1
		Inj Volume	: 5 µl

Acq. Method : D:\LC\LTL\DATE\LTL-9-29\LTL-9-29B 2011-01-12 15-46-16\ADH-30-70-1ML-220NM-60MIN.M

Last changed : 1/12/2011 4:27:17 PM by DXQ
(modified after loading)

Analysis Method : D:\LC\LTL\DATE\LTL-9-29\LTL-9-29B 2011-01-12 15-46-16\064-0101.D\DA.M (ADH-30-70-1ML-220NM-60MIN.M)

Last changed : 1/24/2011 5:23:26 PM by LTL
(modified after loading)



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VMD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	26.921	BB	1.0181	8.55990e4	1251.12134	96.9249
2	60.809	BB	1.8770	2715.79858	19.20364	3.0751

Totals: 8.83148e4 1270.32498

=====
*** End of Report ***

Instrument 1 1/24/2011 5:23:30 PM LTL

Page 1 of 1

Data File D:\LC\LTL\DATE\LTL-9-30\LTL-9-30A 2011-01-17 19-16-11\005-0201.D
Sample Name: LTL-9-30A

=====


Acq. Operator	: LYY	Seq. Line	: 2
Acq. Instrument	: Instrument 1	Location	: Vial 5
Injection Date	: 1/17/2011 7:28:35 PM	Inj	: 1
		Inj Volume	: 5 µl

Acq. Method : D:\LC\LTL\DATE\LTL-9-30\LTL-9-30A 2011-01-17 19-16-11\ADH-30-70-1ML-220NM-80MIN.M

Last changed : 1/17/2011 8:15:20 PM by LYY
(modified after loading)

Analysis Method : D:\LC\LTL\DATE\LTL-9-30\LTL-9-30A 2011-01-17 19-16-11\005-0201.D\DA.M (ADH-30-70-1ML-220NM-80MIN.M)

Last changed : 1/24/2011 5:06:58 PM by LTL
(modified after loading)



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	16.556	NM	0.7480	7.93428e4	1767.99084	49.4192
2	43.630	EB	1.7742	8.12076e4	676.02759	50.5808

Totals : 1.60550e5 2444.01843

=====
*** End of Report ***

Instrument 1 1/24/2011 5:07:02 PM LTL

Page 1 of 1

Data File D:\LC\LTL\DATE\LTL-9-30\LTL-9-30B 2011-01-22 09-47-32\069-0201.D
Sample Name: LTL-9-30B

=====


Acq. Operator	: THL-7-95-97	Seq. Line	: 2
Acq. Instrument	: Instrument 1	Location	: Vial 69
Injection Date	: 1/22/2011 10:05:00 AM	Inj	: 1
		Inj Volume	: 5 µl

Acq. Method : D:\LC\LTL\DATE\LTL-9-30\LTL-9-30B 2011-01-22 09-47-32\ADH-30-70-1ML-220NM-60MIN.M

Last changed : 1/22/2011 10:53:50 AM by THL-7-95-97
(modified after loading)

Analysis Method : D:\LC\LTL\DATE\LTL-9-30\LTL-9-30B 2011-01-22 09-47-32\069-0201.D\DA.M (ADH-30-70-1ML-220NM-60MIN.M)

Last changed : 1/24/2011 5:08:31 PM by LTL
(modified after loading)



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: WVD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	16.371	MM	0.9566	1.98583e5	3459.97070	94.5218
2	44.172	MM	1.8286	1.15092e4	104.90173	5.4782

Totals: 2.10092e5 3564.87243


=====
*** End of Report ***

Instrument 1 1/24/2011 5:08:35 PM LTL

Page 1 of 1

Data File D:\LC\LTL\DATE\LTL-11-13\LTL-11-13A 2011-06-01 08-29-22\034-0201.D
Sample Name: LTL-11-13A

```
=====
Acq. Operator   : LTL                               Seq. Line :    2
Acq. Instrument : Instrument 1                     Location  : Vial 34
Injection Date  : 6/1/2011 8:41:57 AM              Inj       :    1
                                                    Inj Volume: 5 µl
Acq. Method     : D:\LC\LTL\DATE\LTL-11-13\LTL-11-13A 2011-06-01 08-29-22\ADH-30-70-1ML-
                  220NM-80MIN.M
Last changed    : 11/27/2010 11:06:07 AM by LTL
Analysis Method : D:\LC\LTL\DATE\LTL-11-13\LTL-11-13A 2011-06-01 08-29-22\034-0201.D\DA.M (
                  ADH-30-70-1ML-220NM-80MIN.M)
Last changed    : 6/1/2011 3:20:14 PM by LTL
                  (modified after loading)
=====
```



Area Percent Report

```
=====
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs
=====
```

Signal 1: WVD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	10.555	VB	0.3760	1.73337e4	686.65393	50.0591
2	12.879	EB	0.4580	1.72928e4	566.58771	49.9409

```
Totals :                      3.46265e4  1253.24164
=====
```


*** End of Report ***

Instrument 1 6/1/2011 3:20:18 PM LTL

Page 1 of 1

Data File D:\LC\RTL\DATE\RTL-11-13\RTL-11-13B 2011-06-01 15-01-45\035-0101.D
Sample Name: RTL-11-13B

```
=====
Acq. Operator   : LTL                               Seq. Line :    1
Acq. Instrument : Instrument 1                       Location  : Vial 35
Injection Date  : 6/1/2011 3:03:17 PM                Inj       :    1
                                                    Inj Volume: 5 µl
Acq. Method     : D:\LC\RTL\DATE\RTL-11-13\RTL-11-13B 2011-06-01 15-01-45\ADH-30-70-1ML-
                  220NM-25MIN.M
Last changed    : 6/1/2011 3:16:55 PM by LTL
                  (modified after loading)
Analysis Method : D:\LC\RTL\DATE\RTL-11-13\RTL-11-13B 2011-06-01 15-01-45\035-0101.D\DA.M (
                  ADH-30-70-1ML-220NM-25MIN.M)
Last changed    : 6/1/2011 3:19:45 PM by LTL
                  (modified after loading)
=====
```



Area Percent Report

```
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Use Multiplier & Dilution Factor with ISTDs
```

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	10.510	NM	0.4163	1.70504e4	682.63660	94.6384
2	12.816	NM	0.4792	965.96259	33.59390	5.3616

Totals : 1.80164e4 716.23050

*** End of Report ***

Instrument 1 6/1/2011 3:19:50 PM LTL

Page 1 of 1

Data File D:\LC\LTL\DATE\LTL-11-28\LTL-11-28 2011-06-09 12-10-08\063-0401.D
Sample Name: LTL-11-14A

=====


Acq. Operator	: LTL	Seq. Line	: 4
Acq. Instrument	: Instrument 1	Location	: Vial 63
Injection Date	: 6/9/2011 2:06:07 PM	Inj	: 1
		Inj Volume	: 5 µl

Acq. Method : D:\LC\LTL\DATE\LTL-11-28\LTL-11-28 2011-06-09 12-10-08\ADH-30-70-1ML-220NM-40MIN-NOT.M

Last changed : 6/9/2011 2:30:27 PM by LTL
(modified after loading)

Analysis Method : D:\LC\LTL\DATE\LTL-11-28\LTL-11-28 2011-06-09 12-10-08\063-0401.D\DA.M (ADH-30-70-1ML-220NM-40MIN-NOT.M)

Last changed : 6/13/2011 9:52:05 PM by LTL
(modified after loading)



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: WVD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	9.860	VB	0.3486	2.67065e4	1135.79907	49.7768
2	21.748	BB	0.7475	2.69460e4	536.53448	50.2232


Totals : 5.36525e4 1672.33356

=====
*** End of Report ***

Data File D:\LC\RTL\DATE\RTL-11-28\RTL-11-28 2011-06-09 12-10-08\064-0501.D
Sample Name: RTL-11-28B

=====

Acq. Operator	: LTL	Seq. Line	: 5
Acq. Instrument	: Instrument 1	Location	: Vial 64
Injection Date	: 6/9/2011 2:34:41 PM	Inj	: 1
		Inj Volume	: 5 µl
Acq. Method	: D:\LC\RTL\DATE\RTL-11-28\RTL-11-28 2011-06-09 12-10-08\ADH-30-70-1ML-220NM-40MIN-NOT.M		
Last changed	: 6/9/2011 2:33:21 PM by LTL (modified after loading)		
Analysis Method	: D:\LC\RTL\DATE\RTL-11-28\RTL-11-28 2011-06-09 12-10-08\064-0501.D\DA.M (ADH-30-70-1ML-220NM-40MIN-NOT.M)		
Last changed	: 6/13/2011 9:52:36 PM by LTL (modified after loading)		



Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: WVD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	9.828	VB	0.3489	3.99175e4	1695.51526	94.4627
2	21.724	EB	0.7175	2339.90234	48.84929	5.5373

Totals : 4.22574e4 1744.36454


*** End of Report ***

Data File D:\LC\LTLD\DATE\LTLD-8-54-56\LTLD-8-54-56A 2010-12-07 15-08-23\057-0301.D
Sample Name: LTLD-8-56A

=====

Acq. Operator	: THL	Seq. Line	: 3
Acq. Instrument	: Instrument 1	Location	: Vial 57
Injection Date	: 12/7/2010 4:22:53 PM	Inj	: 1
		Inj Volume	: 5 µl
Acq. Method	: D:\LC\LTLD\DATE\LTLD-8-54-56\LTLD-8-54-56A 2010-12-07 15-08-23\ADH-30-70-1ML-220NM-60MIN.M		
Last changed	: 12/7/2010 3:06:41 PM by THL		
Analysis Method	: D:\LC\LTLD\DATE\LTLD-8-54-56\LTLD-8-54-56A 2010-12-07 15-08-23\057-0301.D\DA.M (ADH-30-70-1ML-220NM-60MIN.M)		
Last changed	: 12/7/2010 7:02:41 PM by THL		

(modified after loading)



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs


Signal 1: WVD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	20.648	VB	0.8054	1.20859e5	2230.42065	50.2322
2	56.218	EBA	2.1804	1.19742e5	814.13837	49.7678
Totals :				2.40601e5	3044.55902	

Data File D:\LC\LTL\DATE\LTL-9-29\LTL-9-29D 2011-01-12 18-44-26\066-0101.D
Sample Name: LTL-9-29D

```
=====
Acq. Operator   : DXQ                      Seq. Line :    1
Acq. Instrument : Instrument 1              Location  : Vial 66
Injection Date  : 1/12/2011 6:46:04 PM     Inj       :    1
                                           Inj Volume: 5 µl

Acq. Method     : D:\LC\LTL\DATE\LTL-9-29\LTL-9-29D 2011-01-12 18-44-26\ADH-30-70-1ML-220NM-
                                           80MIN.M
Last changed    : 11/27/2010 11:06:07 AM by LTL
Analysis Method : D:\LC\LTL\DATE\LTL-9-29\LTL-9-29D 2011-01-12 18-44-26\066-0101.D\DA.M (
ADH-30-70-1ML-220NM-80MIN.M)
Last changed    : 1/24/2011 4:55:59 PM by LTL
                  (modified after loading)
=====
```



Area Percent Report

```
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs
```

Signal 1: VMD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	14.125	MM	0.5796	6.93170e4	1993.36377	93.0956
2	61.931	MM	2.4289	5140.88037	35.27583	6.9044

Totals : 7.44578e4 2028.63960

Instrument 1 1/24/2011 4:56:03 PM LTL

Page 1 of 1

Data File D:\LC\LTL\DATE\LTL-8-54-56\LTL-8-54-56A 2010-12-07 15-08-23\058-0401.D
Sample Name: LTL-8-55A

=====


Acq. Operator	: THL	Seq. Line	: 4
Acq. Instrument	: Instrument 1	Location	: Vial 58
Injection Date	: 12/7/2010 5:24:08 PM	Inj	: 1
		Inj Volume	: 5 µl

Acq. Method : D:\LC\LTL\DATE\LTL-8-54-56\LTL-8-54-56A 2010-12-07 15-08-23\ADH-30-70-1ML-220NM-60MIN.M

Last changed : 12/7/2010 5:29:53 PM by THL
(modified after loading)

Analysis Method : D:\LC\LTL\DATE\LTL-8-54-56\LTL-8-54-56A 2010-12-07 15-08-23\058-0401.D\DA.M (ADH-30-70-1ML-220NM-60MIN.M)

Last changed : 12/7/2010 7:04:36 PM by THL
(modified after loading)



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: WVD1 A, Wavelength=220 nm


Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	13.348	BB	0.4798	2.60438e4	801.07672	49.6298
2	56.862	BB	2.0802	2.64323e4	187.64384	50.3702

Totals : 5.24761e4 988.72057

=====
*** End of Report ***

Data File D:\LC\LTL\DATE\LTL-9-29\LTL-9-29C 2011-01-12 16-54-15\065-0101.D
Sample Name: LTL-9-29C

```
=====
Acq. Operator   : DXQ                               Seq. Line :    1
Acq. Instrument : Instrument 1                       Location  : Vial 65
Injection Date  : 1/12/2011 4:55:36 PM              Inj       :    1
                                                    Inj Volume: 5 µl
Acq. Method     : D:\LC\LTL\DATE\LTL-9-29\LTL-9-29C 2011-01-12 16-54-15\ADH-30-70-1ML-220NM-
60MIN.M
Last changed    : 1/12/2011 5:28:48 PM by DXQ
                  (modified after loading)
Analysis Method : D:\LC\LTL\DATE\LTL-9-29\LTL-9-29C 2011-01-12 16-54-15\065-0101.D\DA.M (
ADH-30-70-1ML-220NM-60MIN.M)
Last changed    : 1/24/2011 5:24:14 PM by LTL
                  (modified after loading)
=====
```



Area Percent Report

```
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Use Multiplier & Dilution Factor with ISTDs
```

Signal 1: VM01 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	21.435	VB	1.0236	3.18022e5	3682.40796	88.8348
2	61.624	EB	2.3637	3.99707e4	250.91745	11.1652

Totals : 3.57993e5 3933.32541

*** End of Report ***

Instrument 1 1/24/2011 5:24:17 PM LTL

Page 1 of 1

Data File D:\LC\LTL\DATE\LTL-8-64-67\LTL-8-64-67A-1 2010-11-27 11-08-15\050-0201.D
Sample Name: LTL-8-64A

=====


Acq. Operator	: LTL	Seq. Line	: 2
Acq. Instrument	: Instrument 1	Location	: Vial 50
Injection Date	: 11/27/2010 11:20:46 AM	Inj	: 1
		Inj Volume	: 5 µl

Acq. Method : D:\LC\LTL\DATE\LTL-8-64-67\LTL-8-64-67A-1 2010-11-27 11-08-15\ADH-30-70-
IML-22ONM-80MIN.M

Last changed : 11/27/2010 11:06:07 AM by LTL

Analysis Method : D:\LC\LTL\DATE\LTL-8-64-67\LTL-8-64-67A-1 2010-11-27 11-08-15\050-0201.D\
DA.M (ADH-30-70-IML-22ONM-80MIN.M)

Last changed : 11/27/2010 2:34:39 PM by LTL
(modified after loading)



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: WVD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	22.988	EV	0.8982	6.75650e4	1114.21472	49.8881
2	39.349	EE	1.5892	6.78681e4	633.45526	50.1119

Totals : 1.35433e5 1747.66998

Instrument 1 11/27/2010 2:34:43 PM LTL

Page 1 of 1

Data File D:\LC\LQH\DATE\LQH-3-85-86\LQH-3-85-LTL-7-9 2011-01-24 11-31-41\100-0701.D
Sample Name: LTL-8-64B

=====


Acq. Operator	: LTL	Seq. Line	: 7
Acq. Instrument	: Instrument 1	Location	: Vial 100
Injection Date	: 1/24/2011 2:21:31 PM	Inj	: 1
		Inj Volume	: 5 µl

Acq. Method : D:\LC\LQH\DATE\LQH-3-85-86\LQH-3-85-LTL-7-9 2011-01-24 11-31-41\ADH-30-70-
IML-22ONM-50MIN.M

Last changed : 11/29/2010 10:38:15 AM by THL

Analysis Method : D:\LC\LQH\DATE\LQH-3-85-86\LQH-3-85-LTL-7-9 2011-01-24 11-31-41\100-0701.
D\DA.M (ADH-30-70-IML-22ONM-50MIN.M)

Last changed : 1/24/2011 3:12:49 PM by LTL
(modified after loading)



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: WVD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	23.903	EB	0.9536	7.14252e4	1109.23816	96.6124
2	42.018	MM	1.7217	2504.43726	24.24403	3.3876

Totals : 7.39296e4 1133.48219

Data File D:\LC\RTL\DATE\RTL-8-64-67\RTL-8-64-67A-1 2010-11-27 11-08-15\060-0401.D
Sample Name: RTL-8-67A

=====


Acq. Operator	: LTL	Seq. Line	: 4
Acq. Instrument	: Instrument 1	Location	: Vial 60
Injection Date	: 11/27/2010 12:53:28 PM	Inj	: 1
		Inj Volume	: 5 µl

Acq. Method : D:\LC\RTL\DATE\RTL-8-64-67\RTL-8-64-67A-1 2010-11-27 11-08-15\ASH-10-90-
IML-220NM-60MIN.M

Last changed : 8/30/2010 5:07:19 PM by LTL

Analysis Method : D:\LC\RTL\DATE\RTL-8-64-67\RTL-8-64-67A-1 2010-11-27 11-08-15\060-0401.D\
DA.M (ASH-10-90-IML-220NM-60MIN.M)

Last changed : 11/27/2010 2:34:10 PM by LTL
(modified after loading)



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VM01 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	42.141	MF	3.9815	1.43267e4	59.97124	50.2608
2	51.664	FM	4.9204	1.41780e4	48.02431	49.7392
Totals :				2.85047e4	107.99556	

Instrument 1 11/27/2010 2:34:15 PM LTL

Page 1 of 1

data File D:\LC\RTL\DATE\RTL-8-62-67B\RTL-8-62-67B 2010-11-29 10-38-40\070-0101.D
Sample Name: RTL-8-67B

=====


Acq. Operator	: THL	Seq. Line	: 1
Acq. Instrument	: Instrument 1	Location	: Vial 70
Injection Date	: 11/29/2010 10:40:14 AM	Inj	: 1
		Inj Volume	: 5 µl

Acq. Method : D:\LC\RTL\DATE\RTL-8-62-67B\RTL-8-62-67B 2010-11-29 10-38-40\ASH-10-90-
IML-220NM-60MIN.M

Last changed : 8/30/2010 5:07:19 PM by LTL

Analysis Method : D:\LC\RTL\DATE\RTL-8-62-67B\RTL-8-62-67B 2010-11-29 10-38-40\070-0101.D\
DA.M (ASH-10-90-IML-220NM-60MIN.M)

Last changed : 11/29/2010 12:15:15 PM by THL
(modified after loading)



Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: WVD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Area %s	Height [mAU]	Area %
1	41.145	MM	3.1896	7466.06641	39.01257	3.0014	
2	48.184	MM	5.2990	2.41287e5	758.91125	96.9986	
Totals :				2.48754e5	797.92382		

Instrument 1 11/29/2010 12:15:19 PM THL

Page 1 of 1

Data File D:\LC\LTL\DATE\LTL-8-62\LTL-8-62A 2010-11-26 20-04-25\049-0101.D
Sample Name: LTL-8-62A

=====


Acq. Operator	: LTL	Seq. Line	: 1
Acq. Instrument	: Instrument 1	Location	: Vial 49
Injection Date	: 11/26/2010 8:06:11 PM	Inj	: 1
		Inj Volume	: 5 µl

Acq. Method : D:\LC\LTL\DATE\LTL-8-62\LTL-8-62A 2010-11-26 20-04-25\ASH-10-90-1ML-220NM.
M

Last changed : 6/25/2010 8:30:46 AM by LTL

Analysis Method: D:\LC\LTL\DATE\LTL-8-62\LTL-8-62A 2010-11-26 20-04-25\049-0101.D\A.M (ASH-10-90-1ML-220NM.M)

Last changed : 11/29/2010 10:32:58 AM by THL
(modified after loading)



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	11.591	EE	0.8235	2.89142e4	536.81030	50.2248
2	44.676	NM	5.6289	2.86553e4	84.84644	49.7752
Totals :				5.75695e4	621.65675	

Instrument 1 11/29/2010 10:33:02 AM THL

Page 1 of 1

Data File D:\LC\LTL\DATE\LTL-8-62-67B\LTL-8-62-67B 2010-11-29 10-38-40\068-0301.D
Sample Name: LTL-8-62B

=====


Acq. Operator	: THL	Seq. Line	: 3
Acq. Instrument	: Instrument 1	Location	: Vial 68
Injection Date	: 11/29/2010 12:43:17 PM	Inj	: 1
		Inj Volume	: 5 µl

Acq. Method : D:\LC\LTL\DATE\LTL-8-62-67B\LTL-8-62-67B 2010-11-29 10-38-40\ASH-10-90-
1ML-220NM-60MIN.M

Last changed : 8/30/2010 5:07:19 PM by LTL

Analysis Method : D:\LC\LTL\DATE\LTL-8-62-67B\LTL-8-62-67B 2010-11-29 10-38-40\068-0301.D\
DA.M (ASH-10-90-1ML-220NM-60MIN.M)

Last changed : 11/29/2010 3:00:02 PM by THL
(modified after loading)



Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: WVD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	11.473	MM	0.8651	4202.33887	80.96225	3.9337
2	43.767	MM	6.2674	1.02626e5	272.90829	96.0663

Totals : 1.06828e5 353.87054

Instrument 1 11/29/2010 3:00:07 PM THL

Page 1 of 1

Data File D:\LC\LTL\DATE\LTL-8-69\LTL-8-69B 2010-12-02 10-51-14\034-0201.D
Sample Name: LTL-8-69B

=====


Acq. Operator : dxq	Seq. Line : 2
Acq. Instrument : Instrument 1	Location : Vial 34
Injection Date : 12/2/2010 11:03:40 AM	Inj : 1
	Inj Volume : 5 µl

Acq. Method : D:\LC\LTL\DATE\LTL-8-69\LTL-8-69B 2010-12-02 10-51-14\ASH-10-90-1ML-220NM-60MIN.M

Last changed : 8/30/2010 5:07:19 PM by LTL

Analysis Method : D:\LC\LTL\DATE\LTL-8-69\LTL-8-69B 2010-12-02 10-51-14\034-0201.D\DA.M (ASH-10-90-1ML-220NM-60MIN.M)

Last changed : 12/2/2010 2:56:25 PM by dxq
(modified after loading)



Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VMD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	20.978	MM	1.4846	7393.44287	83.00124	4.5895
2	46.342	MM	4.9574	1.53702e5	516.74640	95.4105

Totals : 1.61095e5 599.74764

Instrument 1 12/2/2010 2:56:28 PM dxq


Page 1 of 1

Data File D:\LC\LTL\DATE\LTL-8-62-67B\LTL-8-62-67B 2010-11-29 10-38-40\069-0201.D
Sample Name: LTL-8-63B

=====

Acq. Operator	: THL	Seq. Line	: 2
Acq. Instrument	: Instrument 1	Location	: Vial 69
Injection Date	: 11/29/2010 11:41:40 AM	Inj	: 1
		Inj Volume	: 5 µl
Acq. Method	: D:\LC\LTL\DATE\LTL-8-62-67B\LTL-8-62-67B 2010-11-29 10-38-40\ASH-10-90-1ML-220NM-60MIN.M		
Last changed	: 8/30/2010 5:07:19 PM by LTL		
Analysis Method	: D:\LC\LTL\DATE\LTL-8-62-67B\LTL-8-62-67B 2010-11-29 10-38-40\069-0201.D\DA.M (ASH-10-90-1ML-220NM-60MIN.M)		
Last changed	: 11/29/2010 2:56:25 PM by THL		

(modified after loading)



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VMD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	17.115	MM	0.9318	4501.31982	80.51328	4.3593
2	33.193	MF	2.3975	9.87566e4	686.52856	95.6407
Totals :				1.03258e5	767.04184	

Instrument 1 11/29/2010 2:56:29 PM THL

Page 1 of 1

Data File D:\LC\LTL\DATE\LTL-11-29\LTL-11-29B 2011-06-10 21-33-54\034-0101.D
Sample Name: LTL-11-29B

=====


Acq. Operator : LTL	Seq. Line : 1
Acq. Instrument : Instrument 1	Location : Vial 34
Injection Date : 6/10/2011 9:35:23 PM	Inj : 1
	Inj Volume : 5 µl

Acq. Method : D:\LC\LTL\DATE\LTL-11-29\LTL-11-29B 2011-06-10 21-33-54\ADH-30-70-1ML-220NM-40MIN-NOT.M

Last changed : 6/9/2011 12:11:50 PM by hzl

Analysis Method : D:\LC\LTL\DATE\LTL-11-29\LTL-11-29B 2011-06-10 21-33-54\034-0101.D\DA.M (ADH-30-70-1ML-220NM-40MIN-NOT.M)

Last changed : 6/10/2011 9:48:50 PM by LTL
(modified after loading)



Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	7.351	MM	0.3504	6.81412e4	3241.05688	96.9255
2	11.095	MM	0.3925	2161.48486	91.78539	3.0745

Totals : 7.03027e4 3332.84227

*** End of Report ***

Data File D:\LC\LTL\DATE\LTL-11-19\LTL-11-19A 2011-06-02 09-41-21\022-0101.D
Sample Name: LTL-11-19

=====


Acq. Operator : LTL	Seq. Line : 1
Acq. Instrument : Instrument 1	Location : Vial 22
Injection Date : 6/2/2011 9:43:03 AM	Inj : 1
	Inj Volume : 5 µl

Acq. Method : D:\LC\LTL\DATE\LTL-11-19\LTL-11-19A 2011-06-02 09-41-21\ADH-30-70-1ML-220NM-80MIN.M

Last changed : 11/27/2010 11:06:07 AM by LTL

Analysis Method : D:\LC\LTL\DATE\LTL-11-19\LTL-11-19A 2011-06-02 09-41-21\022-0101.D\DA.M (ADH-30-70-1ML-220NM-80MIN.M)

Last changed : 6/3/2011 4:31:05 PM by THL
(modified after loading)



Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	17.737	VB	0.6916	7.16663e4	1539.65735	49.7176
2	34.108	EB	1.3716	7.24803e4	782.70056	50.2824

Totals : 1.44147e5 2322.35791

*** End of Report ***

Instrument 1 6/3/2011 4:31:10 PM THL

Data File D:\LC\LTL\DATE\LTL-11-19\LTL-11-19B 2011-06-03 15-22-09\072-0101.D
Sample Name: LTL-11-19B

=====


Acq. Operator	: LTL	Seq. Line	: 1
Acq. Instrument	: Instrument 1	Location	: Vial 72
Injection Date	: 6/3/2011 3:23:32 PM	Inj	: 1
		Inj Volume	: 5 µl

Acq. Method : D:\LC\LTL\DATE\LTL-11-19\LTL-11-19B 2011-06-03 15-22-09\ADH-30-70-1ML-220NM-40MIN.M

Last changed : 4/22/2011 4:36:32 PM by HZL

Analysis Method : D:\LC\LTL\DATE\LTL-11-19\LTL-11-19B 2011-06-03 15-22-09\072-0101.D\DA.M (ADH-30-70-1ML-220NM-40MIN.M)

Last changed : 6/3/2011 4:30:09 PM by THL
(modified after loading)



Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	17.877	MM	0.7916	8.05794e4	1696.56726	96.4331
2	34.689	MM	1.3949	2980.48950	35.61176	3.5669

Totals : 8.35599e4 1732.17902

*** End of Report ***

Data File D:\LC\LTL\DATE\LTL-9-36\LTL-9-36A 2011-01-20 10-08-49\075-0201.D
Sample Name: LTL-9-36A

=====


Acq. Operator	: THL	Seq. Line	: 2
Acq. Instrument	: Instrument 1	Location	: Vial 75
Injection Date	: 1/20/2011 10:21:18 AM	Inj	: 1
		Inj Volume	: 5 µl

Acq. Method : D:\LC\LTL\DATE\LTL-9-36\LTL-9-36A 2011-01-20 10-08-49\ADH-30-70-1ML-220NM-80MIN.M

Last changed : 11/27/2010 11:06:07 AM by LTL

Analysis Method : D:\LC\LTL\DATE\LTL-9-36\LTL-9-36A 2011-01-20 10-08-49\075-0201.D\DA.M (ADH-30-70-1ML-220NM-80MIN.M)

Last changed : 1/24/2011 5:02:35 PM by LTL
(modified after loading)



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: WVD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	17.495	VB	0.7189	5.09878e4	1053.68652	50.0661
2	24.399	EB	0.9350	5.08531e4	819.56921	49.9339
Totals :				1.01841e5	1873.25574	

Instrument 1 1/24/2011 5:02:39 PM LTL

Page 1 of 1

Data File D:\LC\LTL\DATE\LTL-9-36-37B\LTL-9-36-37B 2011-01-22 11-00-18\080-0201.D
Sample Name: LTL-9-37B

=====


Acq. Operator	: THL-7-95-97	Seq. Line	: 2
Acq. Instrument	: Instrument 1	Location	: Vial 80
Injection Date	: 1/22/2011 11:33:18 AM	Inj	: 1
		Inj Volume	: 5 µl

Acq. Method : D:\LC\LTL\DATE\LTL-9-36-37B\LTL-9-36-37B 2011-01-22 11-00-18\ADH-30-70-
1ML-22ONM-30MIN.M

Last changed : 1/22/2011 10:59:12 AM by THL-7-95-97

Analysis Method : D:\LC\LTL\DATE\LTL-9-36-37B\LTL-9-36-37B 2011-01-22 11-00-18\080-0201.D\
DA.M (ADH-30-70-1ML-22ONM-30MIN.M)

Last changed : 1/24/2011 4:58:15 PM by LTL
(modified after loading)



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	14.904	MM	0.6476	4.11335e4	1058.60535	96.4516
2	17.949	MM	0.7012	1513.26123	35.96942	3.5484

Totals : 4.26467e4 1094.57477

Instrument 1 1/24/2011 4:58:18 PM LTL

Page 1 of 1

Data File D:\LC\LTL\DATE\LTL-9-40\LTL-9-40A 2011-01-21 12-51-05\067-0101.D
Sample Name: LTL-9-40A

=====


Acq. Operator	: THL-7-95-97	Seq. Line	: 1
Acq. Instrument	: Instrument 1	Location	: Vial 67
Injection Date	: 1/21/2011 12:52:36 PM	Inj	: 1
		Inj Volume	: 5 µl

Acq. Method : D:\LC\LTL\DATE\LTL-9-40\LTL-9-40A 2011-01-21 12-51-05\ADH-30-70-IML-220NM-80MIN.M

Last changed : 11/27/2010 11:06:07 AM by LTL

Analysis Method: D:\LC\LTL\DATE\LTL-9-40\LTL-9-40A 2011-01-21 12-51-05\067-0101.D\DA.M (ADH-30-70-IML-220NM-80MIN.M)

Last changed : 1/24/2011 5:05:26 PM by LTL
(modified after loading)



Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VM01 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	12.429	MM	0.4706	3.54005e4	1253.84875	49.7170
2	22.911	MM	0.9849	3.58035e4	605.87762	50.2830
Totals :				7.12040e4	1859.72638	

Instrument 1 1/24/2011 5:05:30 PM LTL

Page 1 of 1

Data File D:\LC\LTL\DATE\LTL-9-36-37B\LTL-9-36-37B 2011-01-22 11-00-18\079-0301.D
Sample Name: LTL-9-40B

=====


Acq. Operator	: THL-7-95-97	Seq. Line	: 3
Acq. Instrument	: Instrument 1	Location	: Vial 79
Injection Date	: 1/22/2011 12:04:54 PM	Inj	: 1
		Inj Volume	: 5 µl

Acq. Method : D:\LC\LTL\DATE\LTL-9-36-37B\LTL-9-36-37B 2011-01-22 11-00-18\ADH-30-70-
IML-220NM-30MIN.M

Last changed : 1/22/2011 10:59:12 AM by THL-7-95-97

Analysis Method : D:\LC\LTL\DATE\LTL-9-36-37B\LTL-9-36-37B 2011-01-22 11-00-18\079-0301.D\
DA.M (ADH-30-70-IML-220NM-30MIN.M)

Last changed : 1/24/2011 4:58:58 PM by LTL
(modified after loading)



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	12.404	MM	0.5008	6.69852e4	2229.08105	97.4289
2	22.693	MM	0.8975	1767.69250	32.82574	2.5711
Totals :				6.87529e4	2261.90680	